

## Hypervision Surgical Raises £17 Million Series A to Power Surgical Intelligence Through Hyperspectral Vision

London, United Kingdom | 29 April 2026

Hypervision Surgical (“Hypervision”), a pioneer in real-time hyperspectral imaging for surgery, today announced the successful closing of its oversubscribed **£17 million Series A financing round**, led by Heal Capital with participation from Angelini Ventures, IP Group, and Daycrest. The round also includes follow-on investment from existing investors HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures.

The financing further includes strategic investment from the SINC Fund managed by SAGES Ingenuity, the for-profit innovation arm subsidiary of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) – a leading global surgical society – and Macmillan Cancer Support, the UK’s leading cancer charity. Their participation represents strong validation from both the global surgical community and leading cancer organisations.

The Series A financing will accelerate commercial deployment of Hypervision’s **Hyperspectral Intelligence®** platform, expand clinical adoption, and advance development of the company’s next-generation hyperspectral sensing technology – co-developed with **imec**, the world’s leading independent nanoelectronics R&D hub. This strategic venture partnership includes design, development and manufacturing of Hypervision’s new spectral sensor at imec.

Michael Ebner, CEO and Co-Founder of Hypervision Surgical, said: *“This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision. By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery – giving surgeons real-time insights into tissue that were previously impossible to access.”*

Christian Lautner, Founding Managing Partner, Heal Capital, said: *“Surgical AI has made impressive progress using conventional cameras, but it ultimately faces a ceiling – it captures how tissue looks, not what is happening beneath the surface. Hypervision removes that limitation by delivering real-time, quantitative insights into tissue physiology at the pixel level. We*

*believe this represents the sensing layer on which the next generation of surgical systems will be built – one that will make surgery measurably safer. That’s why we are proud to lead this round.”*

Steven D. Schwaitzberg, MD, President of SAGES Ingenuity, said: *“The SAGES Investment Network Collaborative (SINC) is thrilled to have had the chance to review and join the investment opportunity that Hypervision represents. Enhancing the capabilities around non-contrast visualization is truly a step forward in smarter imaging.”*

As part of the financing, **Rick Mangat** joins Hypervision’s Board of Directors. A pioneer in surgical imaging and the founder of NOVADAQ (acquired by Stryker), his fluorescence imaging-based technology widely powers leading commercial vision systems for robotic, laparoscopic, and open surgery.

### **Building a New Layer of Surgical Intelligence**

Despite advances in digital and robotic surgery, surgeons still rely largely on subjective visual assessment to guide critical intraoperative decisions. Hypervision is addressing this fundamental limitation with the world’s first regulatory-cleared real-time hyperspectral imaging platform for surgery, delivering quantitative tissue insights beyond human vision.

At the core of the company’s approach is **Hyperspectral Intelligence®**, Hypervision’s platform technology combining proprietary on-chip spectral sensing, patented AI analytics, and a cloud-scalable architecture. Together, these technologies transform surgical imaging into real-time, data-driven decision support, generating previously invisible pixel-level insights into tissue physiology and composition during surgery.

This architecture creates a scalable intelligence layer for surgical vision systems across open, minimally invasive, robotic, and microscopic platforms, transforming conventional surgical cameras into data-rich diagnostic tools. In doing so, Hypervision shifts surgical imaging from a static, hardware-limited model



to a flexible, software-centric paradigm designed for continuous evolution.

### **Strong Clinical and Strategic Momentum**

**HYPERSNAP®**, Hypervision's first commercial surgical system, represents the initial clinical deployment of Hyperspectral Intelligence®. It is built on the NVIDIA IGX platform, leveraging its high-performance edge computing capabilities to power real-time AI inference in the operating room, and its software-defined architecture to support flexible integration and deployment models. HYPERSNAP® is certified in the UK and cleared by the US FDA for open and minimally invasive general surgery, providing continuous, dye-free measurement of tissue oxygenation while preserving natural colour information as seen by the human eye. As part of its clearance, the FDA issued a new product code for AI/ML-based real-time video augmentation in imaging systems used in endoscopic or open surgical procedures, recognising Hypervision's novel approach to data-driven surgical vision.

By capturing spectral signatures invisible to the human eye, HYPERSNAP® enables surgeons to assess tissue viability in real time during critical steps such as bowel transection for cancer patients. This capability may help reduce anastomotic leakage, one of the most severe complications in gastrointestinal surgery. Anastomotic leaks occur in up to 15% of colorectal procedures and are associated with cancer recurrence, emergency reinterventions, prolonged ICU stays, and costs exceeding \$50,000 per case.

HYPERSNAP® was previously selected for the FDA's Safer Technologies Program (STeP), highlighting its potential to improve the safety of existing surgical treatments. Early clinical evaluations in colorectal surgery are underway with selected clinical partners in the UK, with initial results accepted for presentation at the SAGES Annual Meeting, one of the world's leading surgical conferences.

Looking ahead, the company aims to integrate **Hyperspectral Intelligence®** across laparoscopic, robotic, microscopic, and endoscopic surgical platforms – enabling data-rich surgical vision across hundreds of millions of procedures annually

--- END ---

### **Media Contact**

media@hypervisionsurgical.com

### **About**

Hypervision Surgical is a medical technology company and a King's College London spin-out pioneering hyperspectral imaging for surgery. Its Hyperspectral Intelligence® platform integrates proprietary spectral sensing and patented AI analytics to create a new intelligence layer for surgery, delivering quantitative tissue insights beyond human vision and powering the next generation of intelligent surgical imaging systems. <https://hypervisionsurgical.com>.

Heal Capital is one of Europe's leading dedicated investment funds for integrated HealthTech, with a total investment volume of over €200M backed by private health insurers, the European Investment Fund (EIF), and health industry leaders. We back mission-driven founders with capital and direct access to the healthcare system, investing €1-5M from pre-seed to Series A across Europe. <https://www.healcapital.com>.

SAGES Ingenuity (SI) is a California based corporation that is the innovation subsidiary of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). SI manages the SAGES Investment Network Collaborative (SINC) fund which invests in early stage opportunities with translational potential. In addition, it offers curated feedback and consulting services that bring the insight of procedural expertise to the medical device community. <https://www.sages-ingenuity.com>

